A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
about
Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerCD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.Sorafenib cardiotoxicity increases mortality after myocardial infarction.Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.Tyrosine kinase inhibitors: Multi-targeted or single-targeted?Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitorsMass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapiesNew antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondInhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growthPhase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancerA double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewOverexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer.Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinomaNew oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.Sorafenib in non-small cell lung cancer.Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?Safety and feasibility of targeted agent combinations in solid tumours.EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.New treatment options for lung adenocarcinoma--in view of molecular background.An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.Fatal interstitial lung disease after addition of sorafenib to a patient with lung adenocarcinoma who had failed to improve with erlotinib alone.Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.Sorafenib for lung cancer: is the "Battle" still open?Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
P2860
Q27693185-980A400B-1246-4735-864D-D674F6CEE693Q30240170-04B9BFAC-843B-45D8-8F30-01D6AE6C37CAQ33572728-10D3BE6C-4293-4184-AA84-700297568815Q33630819-ACE789AC-C399-4F17-96F3-8283ED147081Q33681995-5AA551FF-097E-47EB-B3EA-ACE2D066CBC1Q34298000-D3F0B6C4-1F94-4F33-B5FF-D8E53CA7234DQ34754045-549249F5-8A48-4AB5-B558-EA8E027F44E6Q34983846-0D42649E-E6F9-49E4-8947-8C0DEE6959E2Q35115436-DC0CBD06-07BC-4B08-B5CC-667071FCC41EQ35212644-157328E6-00CB-494B-90CA-E5A2D44CC07AQ35238008-0114DDE9-3D75-4502-BCFE-170E53EE0173Q35549063-9038C181-90C9-4F49-96D8-986FDB2E2FCAQ35660763-1916B2EF-D30D-467D-BCEA-A98D089F502DQ35928707-6FDD28AD-96CC-4291-9335-08BA84C90B09Q35986273-53C67ED2-1BD7-455F-B754-0111EAEEA898Q36241287-23403F07-1BE4-481B-AA3D-B87F88E2B5CAQ36270115-9EBA9367-26D6-405E-987C-7EBAAC93BF2BQ36316437-177DA144-4407-4457-9E2D-E971E0430FD8Q36419366-6DDDA051-7349-4861-A967-3BDAF31F8DDAQ36713494-470C8B3C-E2F0-4129-850D-2932588CF8DCQ36822204-F25803FB-5D99-454D-9DBB-558A02D2A28FQ36859958-0F2669CD-6E3A-4BE4-9B81-18BE7AC223C5Q38014533-A26AA50A-20C2-4D63-9093-5DB168184015Q38020917-C9196636-E09B-4585-85B0-4E2E822E9251Q38022125-DAE34DB9-7F0D-45BA-A579-2B7F7819509FQ38077440-63F0231B-1C3B-4304-A5A5-31DEF14BF6EAQ38160089-79C542CF-0E6D-466F-A445-18C6932246D5Q38168761-746A8963-AEC9-4122-BDCB-F86DF8AEA70DQ38525073-0A286185-4EF7-465F-A3A4-A698C7D515E5Q38632417-345F051F-F39C-4E7F-8166-92FF4FD85690Q39995038-C41BEC5E-A43B-4D3C-A7A3-7E7049C0252CQ41867909-708DFFC9-1A12-4B78-888F-ACAE9DDA0FBEQ42081830-842D2F6F-1147-4F0F-B327-B525DD4D694EQ43515674-DDF3AACC-C3B1-4BED-AC42-A21CFF4A6E61Q47969048-CD267D64-92DD-4831-9500-AC860E107D32Q49787333-899B31CE-254D-4F69-A4D5-CFB3815130A6Q50675249-35D9969C-0A99-4184-8BCA-22E95C17D321Q52627568-F12F4955-179A-4164-938F-12F8393935EAQ53277355-8E55C203-1678-457B-A636-7DF581F1E2DCQ54291692-77131DD6-B73B-46AB-9C35-18B4864C545E
P2860
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A multicenter phase II study o ...... ed non-small cell lung cancer.
@en
A multicenter phase II study o ...... ed non-small cell lung cancer.
@nl
type
label
A multicenter phase II study o ...... ed non-small cell lung cancer.
@en
A multicenter phase II study o ...... ed non-small cell lung cancer.
@nl
prefLabel
A multicenter phase II study o ...... ed non-small cell lung cancer.
@en
A multicenter phase II study o ...... ed non-small cell lung cancer.
@nl
P2093
P50
P1476
A multicenter phase II study o ...... ed non-small cell lung cancer.
@en
P2093
Anne-Marie C Dingemans
Daniëlle A M Heideman
Egbert F Smit
Godefridus J Peters
Harry J M Groen
Joline S W Lind
Otto Bekers
Richard J Honeywell
Robert Jan van Suylen
P304
P356
10.1158/1078-0432.CCR-09-3033
P407
P577
2010-04-15T00:00:00Z